Bryn Pharma appoints Board member Sandy Loreaux as CEO

– USA, NC –  Bryn Pharma LLC, a pharmaceutical company dedicated to finding a better way for patients and caregivers to treat anaphylaxis, today announced the appointment of Sandy Loreaux as CEO, effective immediately, replacing Dr. David Dworaczyk who is transitioning as a senior advisor and head of R&D, Regulatory, and production efforts.

“Sandy’s extensive pharmaceutical commercialization and leadership experience will be instrumental to Bryn as we advance UTULY. While Sandy has already made significant contributions to Bryn as a member of our Board of Directors, her day-to-day involvement comes at a critical time to guide us through a successful launch,” said Co-Founder and Chairman, Steve Hartman.

About Sandy Loreaux

Ms. Loreaux has over 25 years of experience in the pharmaceutical industry. Throughout her career, she has worked across multiple therapeutic areas, including allergy and the epinephrine autoinjector space. She most recently led Covis Pharma’s U.S. Operations as U.S. President. Sandy joined Covis after serving as SVP and GM, of U.S. Critical Care for Mallinckrodt Pharmaceuticals. She has led multiple market access organizations and has served as SVP, Head of Market Access at Mallinckrodt Pharmaceuticals, and SVP, Head of Market Access, and Commercial Operations at Bausch Health. Ms. Loreaux spent the first 19 years of her career at Sanofi and its legacy companies in various roles of increasing responsibility across medical affairs, sales, marketing, and market access.

Ms. Loreaux is a pharmacist by training and has a degree from Temple University School of Pharmacy in Philadelphia.

About Bryn Pharma

Bryn Pharma, established in 2017, is a privately held pharmaceutical company founded by patients for patients. Bryn is focused on positively disrupting the existing market for epinephrine autoinjectors by delivering an accessible, easy-to-use alternative that better meets the needs of patients. Bryn Pharma seeks to provide this growing population at risk for anaphylaxis with A Better Way to be prepared for a life-threatening allergic reaction.


- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.